Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4

BACKGROUND: Neratinib is in Phase 3 clinical trials but, unfortunately, the development of resistance is inevitable. Here, we investigated the effects of acquired neratinib resistance on cellular phenotype and the potential mechanism of this resistance. METHODS: Neratinib-resistant variants of HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Breslin, Susan, Lowry, Michelle C, O'Driscoll, Lorraine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344284/
https://www.ncbi.nlm.nih.gov/pubmed/28152547
http://dx.doi.org/10.1038/bjc.2016.445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344284/
https://www.ncbi.nlm.nih.gov/pubmed/28152547
http://dx.doi.org/10.1038/bjc.2016.445

Ejemplares similares